BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25981987)

  • 1. Family with Legius syndrome (neurofibromatosis type 1-like syndrome).
    Sakai N; Maeda T; Kawakami H; Uchiyama M; Harada K; Tsuboi R; Mitsuhashi Y
    J Dermatol; 2015 Jul; 42(7):703-5. PubMed ID: 25981987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
    Brems H; Legius E
    Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
    Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
    JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legius syndrome: A case report.
    Kimura R; Yoshida Y; Maruoka R; Kosaki K; Yamamoto O
    J Dermatol; 2017 Apr; 44(4):459-460. PubMed ID: 28378438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.
    Evans DG; Bowers N; Burkitt-Wright E; Miles E; Garg S; Scott-Kitching V; Penman-Splitt M; Dobbie A; Howard E; Ealing J; Vassalo G; Wallace AJ; Newman W; ; Huson SM
    EBioMedicine; 2016 May; 7():212-20. PubMed ID: 27322474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
    Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
    J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first Slovak Legius syndrome patient carrying the SPRED1 gene mutation.
    Sekelska M; Briatkova L; Olcak T; Bolcekova A; Ilencikova D; Kadasi L; Zatkova A
    Gen Physiol Biophys; 2017 Apr; 36(2):205-210. PubMed ID: 28150585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
    Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
    Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review and update of SPRED1 mutations causing Legius syndrome.
    Brems H; Pasmant E; Van Minkelen R; Wimmer K; Upadhyaya M; Legius E; Messiaen L
    Hum Mutat; 2012 Nov; 33(11):1538-46. PubMed ID: 22753041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.
    Bernier A; Larbrisseau A; Perreault S
    Pediatr Neurol; 2016 Jul; 60():24-29.e1. PubMed ID: 27212418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legius Syndrome and its Relationship with Neurofibromatosis Type 1.
    Denayer E; Legius E
    Acta Derm Venereol; 2020 Mar; 100(7):adv00093. PubMed ID: 32147744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPRED 1 mutations in a neurofibromatosis clinic.
    Muram-Zborovski TM; Stevenson DA; Viskochil DH; Dries DC; Wilson AR; Rong Mao
    J Child Neurol; 2010 Oct; 25(10):1203-9. PubMed ID: 20179001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.
    Pasmant E; Sabbagh A; Hanna N; Masliah-Planchon J; Jolly E; Goussard P; Ballerini P; Cartault F; Barbarot S; Landman-Parker J; Soufir N; Parfait B; Vidaud M; Wolkenstein P; Vidaud D; France RN
    J Med Genet; 2009 Jul; 46(7):425-30. PubMed ID: 19366998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pigmentary findings in neurofibromatosis type 1-like syndrome (Legius syndrome): potential diagnostic dilemmas.
    Stevenson D; Viskochil D
    JAMA; 2009 Nov; 302(19):2150-1. PubMed ID: 19920242
    [No Abstract]   [Full Text] [Related]  

  • 15. Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder.
    Stewart DR; Brems H; Gomes AG; Ruppert SL; Callens T; Williams J; Claes K; Bober MB; Hachen R; Kaban LB; Li H; Lin A; McDonald M; Melancon S; Ortenberg J; Radtke HB; Samson I; Saul RA; Shen J; Siqveland E; Toler TL; van Maarle M; Wallace M; Williams M; Legius E; Messiaen L
    Genet Med; 2014 Jun; 16(6):448-59. PubMed ID: 24232412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Piebaldism, multiple café-au-lait macules, and intertriginous freckling: clinical evidence of a common pathway between KIT and sprouty-related, ena/vasodilator-stimulated phosphoprotein homology-1 domain containing protein 1 (SPRED1).
    Chiu YE; Dugan S; Basel D; Siegel DH
    Pediatr Dermatol; 2013; 30(3):379-82. PubMed ID: 23016555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Café-au-lait macules and intertriginous freckling in piebaldism: clinical overlap with neurofibromatosis type 1 and Legius syndrome.
    Stevens CA; Chiang PW; Messiaen LM
    Am J Med Genet A; 2012 May; 158A(5):1195-9. PubMed ID: 22438235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choroidal abnormalities in café-au-lait syndromes: a new differential diagnostic tool?
    Cassiman C; Casteels I; Jacob J; Plasschaert E; Brems H; Dubron K; Keer KV; Legius E
    Clin Genet; 2017 Apr; 91(4):529-535. PubMed ID: 27716896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epilepsy in Legius syndrome: Coincidence or causation?
    Medina Lemus A; Boelman C; Myers KA
    Am J Med Genet A; 2024 Jun; 194(6):e63547. PubMed ID: 38268057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of five novel SPRED1 germline mutations in Legius syndrome.
    Laycock-van Spyk S; Jim HP; Thomas L; Spurlock G; Fares L; Palmer-Smith S; Kini U; Saggar A; Patton M; Mautner V; Pilz DT; Upadhyaya M
    Clin Genet; 2011 Jul; 80(1):93-6. PubMed ID: 21649642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.